Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

S 64315

Next Previous
Drug Profile

S 64315

Alternative Names: MIK 665; S64315

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier; Vernalis
  • Developer Novartis; Servier; Vernalis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action MCL1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer
  • Phase I Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes

Most Recent Events

  • 19 Sep 2019 Phase-I/II clinical trials in Breast cancer (Second-line therapy or greater, Combination therapy) in Spain (IV) (EudraCT2019-000998-23)
  • 29 Mar 2019 Pharmacodynamics data from a preclinical study in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 29 Mar 2019 Pharmacodynamics data from preclinical trials in Haematological malignancies presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top